Episodes 1-15 of 809
Improving ATTR-CM Diagnosis: Insights on Heart Failure Phenotypes
Heart MattersImproving ATTR-CM Diagnosis: Insights on Heart Failure Phenotypes
Early Initiation of Acoramidis in ATTR-CM: Importance and Long-Term Impacts
Heart MattersEarly Initiation of Acoramidis in ATTR-CM: Importance and Long-Term Impacts
Rivaroxaban as effective as warfarin for left ventricular thrombus post-MI
ACC Action CenterRivaroxaban as effective as warfarin for left ventricular thrombus post-MI
Mobile integrated health program in patients with HF
ACC Action CenterMobile integrated health program in patients with HF
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
ACC Action CenterPhase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
Low-dose apixaban noninferior to full dose in cancer-associated VTE
ACC Action CenterLow-dose apixaban noninferior to full dose in cancer-associated VTE
AI model may accelerate risk stratification of coronary revascularization in ED
ACC Action CenterAI model may accelerate risk stratification of coronary revascularization in ED
Dapagliflozin reduces worsening HF in elderly TAVI patients
ACC Action CenterDapagliflozin reduces worsening HF in elderly TAVI patients
Lorundrostat lowers BP in uncontrolled and treatment-resistant hypertension
ACC Action CenterLorundrostat lowers BP in uncontrolled and treatment-resistant hypertension
Fluid restriction may not be needed in chronic HF
ACC Action CenterFluid restriction may not be needed in chronic HF
Secondary prevention strategy led by nurses reduces MACE risk after an ACS
ACC Action CenterSecondary prevention strategy led by nurses reduces MACE risk after an ACS
Secondary prevention post-ACS: a nurse-led intervention strategy
ACC Action CenterSecondary prevention post-ACS: a nurse-led intervention strategy
Intensive medical therapy does not reduce MACE risk in women with INOCA
ACC Action CenterIntensive medical therapy does not reduce MACE risk in women with INOCA
